Prevention and Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Stem Cell Transplantation

Overview

Journal Curr Opin Hematol

Specialty Hematology

Date 2011 Sep 8

PMID 21897227

Citations 26

Authors

Betul Oran

Marcos de Lima

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Relapse remains a major cause of treatment failure for acute myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo-HCT). Most patients that recur will perish due to low treatment efficacy, toxicity, or frailty issues. This review summarizes recent developments in clinical research and therapeutic applications for prevention and treatment of this complication of transplantation.

Recent Findings: Several groups have demonstrated that monitoring minimal residual disease (MRD) after allo-HCT is feasible and is predictive of impending hematologic recurrence. The introduction of novel antileukemia agents in the preparative regimen, maintenance of remission treatment posttransplant, and early MRD-based therapeutic interventions all have the potential to improve outcomes.

Summary: Innovative basic and clinical investigation is urgently needed to improve treatment and prevention of AML recurrence after allogeneic transplantation.

Citing Articles

A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.

Mroczkowska-Bekarciak A, Wrobel T Oncotarget. 2025; 16:44-50.

PMID: 39907609 PMC: 11798483. DOI: 10.18632/oncotarget.28686.

Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications.

Ouyang D, Ye N, Yang K, Wang Y, Hu L, Chao S Cancers (Basel). 2023; 15(23).

PMID: 38067399 PMC: 10705219. DOI: 10.3390/cancers15235696.

[Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].

Zhao Y, Song Y, Li Z, Yang F, Xu T, Li F Zhonghua Xue Ye Xue Za Zhi. 2023; 44(6):465-471.

PMID: 37550201 PMC: 10450545. DOI: 10.3760/cma.j.issn.0253-2727.2023.06.004.

Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.

Lu Y, Zhang J, Zhao Y, Xiong M, Sun R, Cao X Front Immunol. 2023; 13:1066748.

PMID: 36685540 PMC: 9846785. DOI: 10.3389/fimmu.2022.1066748.

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.

Han T, Sun Y, Liu Y, Yan C, Wang Y, Xu L Front Med. 2021; 15(5):728-739.

PMID: 34279770 DOI: 10.1007/s11684-021-0833-x.